Drugs / ticgio
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04908566 Comparator | May 2021 → Aug 2023 overdue | gastric adenocarcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ticgio | “ticgio 40-60mg bid, d1-14 q3w” NCT04908566 ↗ |